A 48-year-old woman with CKD stage 5 (eGFR 8 mL/min/1.73m²) and hemoglobin 7.2 g/dL is evaluated for anemia management. She has not yet started dialysis. Regarding erythropoiesis-stimulating agents (ESAs) and iron supplementation in CKD anemia, all of the following statements are correct EXCEPT:

Explanation

## CKD Anemia Management: ESA and Iron Strategies **Key Point:** ESA initiation in CKD anemia is **individualized and symptom-driven**, not based on a fixed hemoglobin threshold. The 2021 KDIGO guidelines recommend targeting hemoglobin 10–12 g/dL based on patient tolerance and cardiovascular risk, not automatic initiation at <10 g/dL. ### ESA Initiation: Current Evidence **High-Yield:** The paradigm has shifted from "treat to target" (hemoglobin 13–15 g/dL) to "treat to symptom." The TREAT trial (2009) and subsequent studies showed that aggressive ESA use to raise hemoglobin >13 g/dL increases thromboembolism and mortality without improving outcomes. | Guideline Era | Hemoglobin Target | Rationale | Outcome | |---|---|---|---| | Pre-2009 | 13–15 g/dL | Assumed higher is better | ↑ Thromboembolism, ↑ mortality | | 2009–2021 | 10–12 g/dL (individualized) | Symptom-driven, minimize ESA dose | ↓ Adverse events, maintained QOL | | Current (2021 KDIGO) | 10–12 g/dL (patient-centered) | Avoid rapid correction; assess symptoms | Balanced risk–benefit | **Warning:** Initiating ESA at hemoglobin <10 g/dL as a blanket rule is **outdated**. Current practice is to assess symptoms (fatigue, dyspnea, reduced exercise tolerance) and comorbidities (heart failure, CAD) before starting ESA. Some patients tolerate Hb 8–9 g/dL without symptoms and may not need ESA. ### Iron Management in CKD Anemia **Key Point:** Iron is essential for ESA response. Target **transferrin saturation (TSAT) ≥20%** and **serum ferritin 100–500 ng/mL** (dialysis patients) or **100–300 ng/mL** (non-dialysis CKD). 1. **Oral iron:** First-line for non-dialysis CKD; limited bioavailability (10–15%); GI side effects common 2. **Intravenous iron:** Preferred in dialysis patients; rapid repletion; bypasses GI absorption; risk of iron overload if not monitored **Clinical Pearl:** IV iron is superior in dialysis patients because: - Dialysis removes some iron - Oral iron absorption is impaired in CKD (hepcidin dysregulation) - IV iron achieves target TSAT/ferritin faster - Reduced GI intolerance ### ESA Safety: Thromboembolism and Hypertension **High-Yield:** Rapid correction of anemia with ESA (hemoglobin increase >2 g/dL/month) increases: - Venous thromboembolism (DVT, PE) - Arterial thrombosis (MI, stroke) - Hypertension (via increased blood viscosity, endothelin release) - ESA resistance (iron deficiency, inflammation, ACE inhibitor use) **Mnemonic: ESA Risks — "THROB"** - **T**hromboembolism (VTE, ATE) - **H**ypertension - **R**apid correction (>2 g/dL/month) — avoid - **O**vertreatment (Hb >12 g/dL) — increases mortality - **B**lood viscosity increase ### Why Option 0 Is Incorrect **Reasoning:** The statement "ESAs should be initiated when hemoglobin falls below 10 g/dL" reflects **pre-2009 dogma**. Current KDIGO 2021 guidance is **symptom-driven and individualized**. A patient with Hb 9.5 g/dL who is asymptomatic and has no cardiac risk factors may not need ESA. Conversely, a symptomatic patient with Hb 10.5 g/dL and heart failure may benefit from cautious ESA use. The threshold is not absolute. [cite:KDIGO Anemia in CKD 2021; Harrison 21e Ch 279]